Use of non-peptide nk1 antagonists in a predetermined dose for the treatment of cancer

Abstract

Use of the non-peptide NK1 receptor antagonist, preferably Aprepitant, for the treatment of cancer in predetermined doses. The present invention also describes pharmaceutical compositions comprising said agents, alone or in combination with at least one other active principle, for the treatment of cancer

1 . A method of treating cancer in a mammal, said method comprising administering a composition comprising a non-peptide NK1 receptor antagonist at doses between 5 and 120 mg/kg of weight per day. 
     
     
         2 . The method of  claim 1 , wherein the dose is between 8 and 100 mg/kg of weight per day. 
     
     
         3 . The method of  claim 1 , wherein the dose is between 10 and 80 mg/kg of weight per day. 
     
     
         4 . The method of  claim 1 , wherein the non-peptide NK1 receptor antagonist is selected from the group consisting of: Aprepitant, Vestipitant, Casopitant, Vofopitant, Ezlopitant, Lanepitant, LY-686017, L-733,060, L-732,138, L-703,606, WIN 62,577, CP-122721, TAK-637, and R673, CP-100263, WIN 51708, CP-96345, L-760735, CP-122721, L-758298, L-741671, L-742694, CP-99994, T-2328, and combinations thereof. 
     
     
         5 . The method of  claim 1 , wherein the non-peptide NK1 receptor antagonist is selected from the group consisting of: Aprepitant, Vestipitant, Casopitant, Vofopitant, Ezlopitant and Lanepitant, and combinations thereof. 
     
     
         6 . The method of  claim 1 , wherein the non-peptide NK1 receptor antagonist is Aprepitant. 
     
     
         7 . (canceled) 
     
     
         8 . The method of  claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         9 . The method of  claim 1 , wherein the composition further comprises at least one other active principle B. 
     
     
         10 . The method of  claim 9 , wherein the active principle B is selected from the group 144 consisting of: Chlorambucil, Melphalan, Aldesleukin, 6-Mercaptopurine, 5-Fluorouracil, Ara-c, Bexarotene, Bleomycin, Capecitabine, Carboplatin, Cisplatin, Docetaxel, Doxorubicin, Epirubicin, Fludarabine, Irinotecan Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Rituximab, Vinblastine, Etoposide, Teniposide, Vincristine, Vinorelbine, Imatinib, Erlotinib, Cetuximab, Trastuzumab, and or any combinations thereof. 
     
     
         11 . The method of  claim 9 , wherein the non-peptide NK1 receptor antagonist and the active principle B are administered separately, jointly, or sequentially. 
     
     
         12 . The method of  claim 1 , wherein cancer is selected from the group consisting of gastric cancer, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, endometrial cancer, choriocarcinoma, uterine cervical cancer, lung cancer, thyroid cancer, bladder cancer, prostate cancer, glial tumours of the central nervous system, sarcomas, melanomas, embryonal carcinoma, haematological malignancies, and combinations thereof. 
     
     
         13 . The method of  claim 1 , wherein cancer presents with alteration of the peritumoral environment. 
     
     
         14 . The method of  claim 1 , wherein the cancer that presents with peritumoral alteration shows an increased synthesis of the markers selected from the list consisting of: NF-kB, EGF, VEGF, TNF-α, TGF-α, TGF-β 1, TGF-β 2, TGF-β 3, SPARC, MMP-3; MMP-7, MMP-9, MMP-11, MMP-13, MMP-14 and/or combinations thereof.